Active EZH2 induces and activates, in conjunction with HMGA, tumour-promoting factors and proliferation, repressing differentiating factors such as runt-domain transcription 3 factor (RUNX3), p57 cyclin-CDK inhibitor 1C (CDKN1C), and cadherin 1 (CDH1) [28, 42–49]. Here, CDKN1C is linked to neoplasm.